Abstract More effective options are needed to personalize treatment for relapsed/refractory (R/R) follicular lymphoma (FL) by balancing efficacy, safety, and accessibility. We report efficacy and safety of glofitamab, a CD20xCD3 T‐cell...
Abstract Patient‐reported outcome measures (PROMs) are increasingly used in clinical trials of classical Philadelphia chromosome‐negative myeloproliferative neoplasms (Ph‐negative MPNs; myelofibrosis [MF], polycythemia vera [PV], and...
Abstract DNA hypomethylating agents (HMAs) such as 5‐azacytidine (5‐AZA) are a cornerstone in the treatment of acute myeloid leukemia (AML), but development of resistance represents a major clinical challenge. Apart from epigenetic...
Sustained disease remission with reduced‐intensity allogeneic hematopoietic cell transplant for VEXAS syndromeBhavisha A. Patel,
Ajoy Dias,
Daniele Avila,
Tonya Jenkins,
Lisa Duncan,
Roxanne Merkel,
Alice Fike,
Julie Onyechi,
Xingmin Feng,
Fernanda Gutierrez‐Rodrigues,
Ivana Darden,
Shanni Liu,
Benjamin Turturice,
Jennifer Hendricks,
Erin Flannelly,
Kristen Cole,
Kanak Parmar,
Ruba Shalhoub,
Colin O. Wu,
Jennifer Lotter,
Boeui Kang,
Sachiko Kajigaya,
Corina Gonzalez,
Chuanfeng Wu,
Marcela A. Ferrada,
Jennifer Cuellar‐Rodriguez,
Mary Czech,
Katherine R. Calvo,
Richard W. ChildHemaSphere
· Hematology
· 2026-11-10
Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERICCandida Vitale,
Thomas Chatzikonstantinou,
Christina Papangelou,
Francesca Perutelli,
Maria Chiara Montalbano,
Giulia Bondielli,
Elia Boccellato,
Salem Alshemmari,
Francesco Angotzi,
Miguel Arguello‐Tomas,
Tomas Arpas,
Sandra Bašić‐Kinda,
Sotiria Besikli‐Dimou,
Łukasz Bołkun,
Tomasz Buczek,
Aleksandra Butrym,
Katherine Chapis,
Sofia Chatzileontiadou,
Rosa Collado,
Raul Cordoba Mascuñano,
Lorenzo De Paoli,
Marina Deodato,
Maria Dimou,
David Donaldson,
Joanna Drozd‐SokołowsHemaSphere
· Hematology
· 2026-11-06
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients...
Abstract Exposure of macrophages to iron has been implicated in sterile inflammation through reactive oxygen species (ROS)‐dependent cell pro‐inflammatory activation. Here, we compare the effect of the commonly used oral iron salt, iron...
Abstract Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are the most aggressive forms of cutaneous T‐cell lymphoma and remain associated with a poor prognosis and heterogeneous therapeutic approaches. Recent advances,...
Abstract Lineage switch (LS) is a rare but aggressive immunophenotypic transformation of acute leukemia associated with limited therapeutic options and poor clinical outcome. Although LS has been increasingly recognized in the era of...
Abstract Large B‐cell lymphoma (LBCL) is cured in most patients with first‐line chemoimmunotherapy; however, 30%–40% of patients will have relapsed or refractory (R/R) disease. Of these patients, those with refractory or early relapsed...
Abstract Follicular lymphoma (FL) is the commonest indolent non‐Hodgkin lymphoma. Most patients present with advanced‐stage and are stratified by the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria into high or low tumor...
Improved multistate survival in younger AML patients over timeSjoerd J. F. Hermans,
Jurjen Versluis,
Gert J. Ossenkoppele,
Edo Vellenga,
Thomas Pabst,
Leo F. Verdonck,
Johan Maertens,
Dimitri Breems,
Markus G. Manz,
Bart Biemond,
Jürgen Kuball,
Marinus van Marwijk Kooy,
Mojca Jongen‐Lavrencic,
Peter C. Huijgens,
Jakob Passweg,
Bjørn T. Gjertsen,
Soren Lehmann,
Patrycja Gradowska,
Berna Beverloo,
Peter Valk,
Gerwin Huls,
Liesbeth C. de Wreede,
Bob Löwenberg,
Jan J. CornelissenHemaSphere
· Hematology
· 2026-11-03
Abstract Over the last three decades, HOVON‐SAKK has performed six randomized controlled trials (RCTs) in newly diagnosed younger adults with acute myeloid leukemia (AML). While overall survival (OS) improved over time, no OS benefit...